| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2010 ( Subtotal = $0 ) |
| | 2010 | 2005 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R43DK066880 | A2A ADENOSINE RECEPTOR AGONIST FOR THE TREATMENT OF IBD | 000 | 2 | NIH | 11/11/2009 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $0 ) |
| | 2009 | 2007 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R41AI063671 | SAFETY OF ADENOSINE A2A AGONIST FOR TREATMENT OF SEPSIS | 000 | 2 | NIH | 7/1/2009 | $0 |
|
| Issue Date FY: 2007 ( Subtotal = $1,204,935 ) |
| | 2007 | 2007 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R41AI063671 | SAFETY OF ADENOSINE A2A AGONIST FOR TREATMENT OF SEPSIS | 000 | 2 | NIH | 7/12/2007 | $415,035 |
| | 2007 | 2007 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R44AI048979 | ANTAGONISTS OF A2B ADENOSINE RECEPTORS FOR ASTHMA | 000 | 3 | NIH | 9/7/2007 | $685,117 |
| | 2007 | 2007 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R43DA022110 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF COCAINE ADDICTION | 000 | 1 | NIH | 5/24/2007 | $104,783 |
|
| Issue Date FY: 2006 ( Subtotal = $1,887,634 ) |
| | 2006 | 2006 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R44AI048979 | ANTAGONISTS OF A2B ADENOSINE RECEPTORS FOR ASTHMA | 000 | 2 | NIH | 8/24/2006 | $755,496 |
| | 2006 | 2006 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R41AI063671 | SAFETY OF ADENOSINE A2A AGONIST FOR TREATMENT OF SEPSIS | 000 | 1 | NIH | 6/16/2006 | $861,737 |
| | 2006 | 2006 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R41AI071496 | A2A AR AGONISTS AS ADJUNCT THERAPY AGAINST S. AUREUS SEPSIS | 000 | 1 | NIH | 8/22/2006 | $132,798 |
| | 2006 | 2006 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R41AR052960 | A2A AR AGONISTS FOR RHEUMATOID ARTHRITIS | 000 | 1 | NIH | 8/10/2006 | $137,603 |
|
| Issue Date FY: 2005 ( Subtotal = $2,419,246 ) |
| | 2005 | 2005 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R44DK059677 | ANTAGONISTS OF A2B RECEPTORS IMPROVE INSULIN SENSITIVITY | 000 | 3 | NIH | 3/25/2005 | $697,156 |
| | 2005 | 2005 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R44HL065759 | NOVEL A2A ADENOSINE AGONISTS IN VASCULAR PROTECTION | 000 | 3 | NIH | 8/29/2005 | $811,648 |
| | 2005 | 2005 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R43DK066880 | A2A ADENOSINE RECEPTOR AGONIST FOR THE TREATMENT OF IBD | 000 | 2 | NIH | 9/26/2005 | $335,663 |
| | 2005 | 2005 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R41DK072649 | A2A ADENOSINE AGONISTS FOR DIABETIC NEPHROPATHY | 000 | 1 | NIH | 9/19/2005 | $147,326 |
| | 2005 | 2005 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R44HL080864 | A2A ADENOSINE AGONIST CARDIAC REPERFUSION INJURY | 000 | 1 | NIH | 6/20/2005 | $288,277 |
| | 2005 | 2005 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R41NS051025 | A2A ADENOSINE BLOCKERS FOR PARKINSON'S DISEASE | 000 | 1 | NIH | 1/26/2005 | $139,176 |
|
| Issue Date FY: 2004 ( Subtotal = $1,689,467 ) |
| | 2004 | 2004 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R44HL065759 | NOVEL A2A ADENOSINE AGONISTS IN VASCULAR PROTECTION | 000 | 2 | NIH | 9/17/2004 | $624,818 |
| | 2004 | 2004 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R43DK066880 | A2A ADENOSINE RECEPTOR AGONIST FOR THE TREATMENT OF IBD | 000 | 1 | NIH | 5/21/2004 | $337,360 |
| | 2004 | 2004 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905 | CHARLOTTESVILLE CITY | USA | R44DK059677 | ANTAGONISTS OF A2B RECEPTORS IMPROVE INSULIN SENSITIVITY | 000 | 2 | NIH | 4/9/2004 | $727,289 |
|
| Issue Date FY: 2003 ( Subtotal = $1,394,350 ) |
| | 2003 | 2003 | ADENOSINE THERAPEUTICS, LLC | 107 CAVALIER DRIVE | CHARLOTTESVILLE | VA | 22901 | ALBEMARLE | USA | R42AI046852 | A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION | 000 | 3 | NIH | 5/19/2003 | $427,450 |
| | 2003 | 2003 | ADENOSINE THERAPEUTICS, LLC | 107 CAVALIER DRIVE | CHARLOTTESVILLE | VA | 22901 | ALBEMARLE | USA | R44DK058413 | NOVEL ADENOSINE A2A AGONISTS IN RENAL TISSUE PROTECTION | 000 | 3 | NIH | 8/15/2003 | $394,934 |
| | 2003 | 2003 | ADENOSINE THERAPEUTICS, LLC | 107 CAVALIER DRIVE | CHARLOTTESVILLE | VA | 22901 | ALBEMARLE | USA | R43HL073587 | LONG ACTING AGONISTS OF ADENOSINE A2A RECEPTORS | 000 | 1 | NIH | | $100,885 |
| | 2003 | 2003 | ADENOSINE THERAPEUTICS, LLC | 107 CAVALIER DRIVE | CHARLOTTESVILLE | VA | 22901 | ALBEMARLE | USA | R44NS043093 | A2A ADENOSINE AGONISTS AS NEUROPROTECTANTS | 000 | 3 | NIH | 9/12/2003 | $471,081 |
|
| Issue Date FY: 2002 ( Subtotal = $1,732,779 ) |
| | 2002 | 2002 | ADENOSINE THERAPEUTICS, LLC | 107 CAVALIER DRIVE | CHARLOTTESVILLE | VA | 22901 | ALBEMARLE | USA | R41AI053042 | A2A ADENOSINE AGONISTS ADJ THERAPY FOR SYSTEMIC ANTHRAX | 000 | 1 | NIH | 9/20/2002 | $198,360 |
| | 2002 | 2002 | ADENOSINE THERAPEUTICS, LLC | 107 CAVALIER DRIVE | CHARLOTTESVILLE | VA | 22901 | ALBEMARLE | USA | R42AI046852 | A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION | 000 | 2 | NIH | 5/6/2002 | $516,103 |
| | 2002 | 2002 | ADENOSINE THERAPEUTICS, LLC | 107 CAVALIER DRIVE | CHARLOTTESVILLE | VA | 22901 | ALBEMARLE | USA | R44NS043093 | A2A ADENOSINE AGONISTS AS NEUROPROTECTANTS | 000 | 2 | NIH | 9/15/2002 | $457,679 |
| | 2002 | 2002 | ADENOSINE THERAPEUTICS, LLC | 107 CAVALIER DRIVE | CHARLOTTESVILLE | VA | 22901 | ALBEMARLE | USA | R44NS043093 | A2A ADENOSINE AGONISTS AS NEUROPROTECTANTS | 000 | 1 | NIH | 2/7/2002 | $137,289 |
| | 2002 | 2002 | ADENOSINE THERAPEUTICS, LLC | 107 CAVALIER DRIVE | CHARLOTTESVILLE | VA | 22901 | ALBEMARLE | USA | R44DK058413 | NOVEL ADENOSINE A2A AGONISTS IN RENAL TISSUE PROTECTION | 000 | 2 | NIH | 6/24/2002 | $423,348 |
|
| Issue Date FY: 2001 ( Subtotal = $200,000 ) |
| | 2001 | 2001 | ADENOSINE THERAPEUTICS, LLC | 107 CAVALIER DRIVE | CHARLOTTESVILLE | VA | 22901 | ALBEMARLE | USA | R43AI048979 | ANTAGONIST OF A2B ADENOSINE RECEPTORS FOR ASTHMA | 000 | 1 | NIH | 9/28/2001 | $100,000 |
| | 2001 | 2001 | ADENOSINE THERAPEUTICS, LLC | 107 CAVALIER DRIVE | CHARLOTTESVILLE | VA | 22901 | ALBEMARLE | USA | R43DK059677 | ANTAGONISTS OF A2B RECEPTORS IMPROVE INSULIN SENSITIVITY | 000 | 1 | NIH | 9/13/2001 | $100,000 |
|
| Issue Date FY: 2000 ( Subtotal = $400,000 ) |
| | 2000 | 2000 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905-4632 | CHARLOTTESVILLE CITY | USA | R41AI046852 | A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION | 000 | 1 | NIH | 7/31/2000 | $100,000 |
| | 2000 | 2000 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905-4632 | CHARLOTTESVILLE CITY | USA | R41HL064505 | IMPROVED VASODILATORS FOR PHARMACOLOGICAL STRESS IMAGING | 000 | 1 | NIH | 1/31/2000 | $100,000 |
| | 2000 | 2000 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905-4632 | CHARLOTTESVILLE CITY | USA | R41HL065759 | NOVEL ADENOSINE A2A AGONISTS IN VASCULAR PROTECTION | 000 | 1 | NIH | 7/24/2000 | $100,000 |
| | 2000 | 2000 | ADENOSINE THERAPEUTICS, LLC | PO BOX 4632 | CHARLOTTESVILLE | VA | 22905-4632 | CHARLOTTESVILLE CITY | USA | R41DK058413 | NOVEL ADENOSINE 2A AGONISTS IN RENAL TISSUE PROTECTION | 000 | 1 | NIH | 9/30/2000 | $100,000 |
|
|
